Pancreatic Carcinoma: Chemoradiation Compared With Chemotherapy Alone After Induction Chemotherapy

Inclusion Criteria: * Age \> 18 years * histologically confirmed adenocarcinoma of the pancreas * no evidence of distant metastasis based on computed tomography of the thorax and abdomen * non resectable pancreatic cancer * no evidence of peritoneal carcinosis * ECOG-performance status ≤ 2 * signed study-specific consent form prior to therapy Exclusion Criteria: * fertile patients who refuse effective contraception during study treatment * synchron second malignant neoplasm except basal cell carcinoma of the skin and carcinoma in situ of the cervix after curative therapy * the Inclusion of patients with prior or concurrent malignancy (≤ 5 years prior to enrolment in study) must be discussed * chronic inflammatory disease of the intestine * known allergic reactions on study medication * on-treatment participation on other trials * insufficient liver function: Bilirubin \> 2,0 mg/dl; SGOT, SGPT, alkaline phosphatase, gGT more than 3 times upper limit of normal (after Stent implantation in case of obstructive jaundice); cirrhosis of the liver Child B and C * insufficient bone marrow function: WBC \< 3,0 x 10\^9/l, Platelets \> 100 x 10\^9/l * serum creatinine \> 1,5 mg/dl, creatinin clearance \< 60ml/min (or comparable test) * preexisting uncontrolled cardiac disease, signs of cardiac failure, or rhythm disturbances requiring therapy, myocardial infarction within the past 6 months, unstable angina pectoris, congestive heart failure, New York Heart Association (NYHA) class III or IV heart disease * neurological and/or psychiatric diseases: stroke, dementia, epilepsy, psychosis * active intractable or uncontrollable infection, HIV-infection * prior radiotherapy or chemotherapy